How do I tell if GSK is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Stock

Q: What is the minimum investment for GSK on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in GSK plc American Depositary Shares (Each representing two Ordinary Shares) from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NEW YORK STOCK EXCHANGE, INC. · GSK

Trade GSK

Key stats

Market cap: $101.43B
Price / Earnings ratio: 17.7x
EPS (TTM): $2.88
Volume: Loading
52-week high: $61.70
52-week low: $45.81
Dividend yield: 3.53%
Dividend amount (latest): $0.45
EPS vs analyst estimate: +17.8%Q3 FY25 · $1.48 vs $1.26

Source: third-party data provider, as of November 13, 2026

EPS estimate: analyst consensus

Compare with GSK

Technical indicators

RSI 14: 54.15
MACD 12/26/9: 0.48
EMA 9 of MACD: 0.34
MACD histogram: 0.14
SMA 50: $49.30; Price above SMA 50
EMA 50: $49.80; Price above EMA 50
SMA 200: $52.40; Price below SMA 200
EMA 200: $51.08; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Hold

Based on 1 analyst rating

Strong Sell0

Sell0

Hold1

Buy0

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

53B35B17B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

95B63B31B0

Revenue to Profit

2025

$44.1B

Revenue

$0.0

Cost of revenue

$23.6B

Gross profit

$0.0

Operating expenses

$5.7B

Net income

Earnings

EPS forecast

Actual EPS

$1.13

$1.04

Q1FY25

$1.24

$1.12

Q2FY25

$1.48

$1.26

Q3FY25

$0.66

Q4FY25

$1.15

Q1FY26

The market is expecting earnings per share of $1.15 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.

SectorHealthcare

IndustryDrug Manufacturers - General

Employees66,841

CEOMr. Luke Victor Miels

IPO DateJul 9, 1986

HeadquartersLondon, United Kingdom

Key Executives

Name	Title	Year Born
Mr. Luke Victor Miels	CEO & Director	1974
Ms. Julie Belita Brown A.C.A.	CFO & Executive Director	1962
Dr. Jesse L. Goodman M.D., M.P.H.	Scientific & Medical Expert	1951
Ms. Shobie Ramakrishnan	Chief Digital & Technology Officer	1971
Mr. Tony Wood	Chief Scientific Officer and Head of R&D	—
Mr. James Ford	Senior VP and Group General Counsel of Legal & Compliance	—
Mr. David Simon Redfern BSc (Hons), CA	President of Corporate Development	1966
Ms. Roanne Parry	Chief People Officer	1974
Mr. Philip C. Thomson	President of Global Affairs	—
Mr. Regis Simard	President of Global Supply Chain	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-4.7	+6.6
2022	+2.6	-7.4	+4.8	+3.2	-1.8	+1.1	-22.9	-22.0	-7.1	+9.7	+3.4	+0.3
2023	-0.1	-3.4	+3.9	+0.2	-7.2	+5.4	+0.8	+0.6	+3.5	-1.1	+4.1	+1.3
2024	+5.1	+3.1	+2.0	-2.3	+5.2	-5.8	+1.0	+10.8	-5.9	-8.8	-7.5	-1.4
2025	+3.9	+7.7	+2.1	+5.2	+5.9	-7.8	-4.6	+5.6	+10.8	+3.0	+3.3	+3.9
2026	+4.0	+12.7	-5.3	-6.6	-2.1	+6.3	+0.8	-2.4	-4.9	+4.9	+3.0

Stocks in the same sector

FAQ

Buying GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "GSK", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy GSK by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in GSK plc American Depositary Shares (Each representing two Ordinary Shares) from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, GSK plc American Depositary Shares (Each representing two Ordinary Shares) regularly pays dividends to shareholders. Currently, the estimated dividend yield for GSK is around 3.53% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Stock

Key stats

Compare with GSK

Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

What GSK (GSK) Said on Its Q3 Earnings Call

What GSK (GSK) Said on Its Q3 Earnings Call

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

What GSK (GSK) Said on Its Q3 Earnings Call

What GSK (GSK) Said on Its Q3 Earnings Call

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat

GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GSK beats third-quarter profit estimates, keeps annual targets

GSK beats third-quarter profit estimates, keeps annual targets

GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

GSK to nearly double cancer drugs in trials, WSJ reports

GSK to nearly double cancer drugs in trials, WSJ reports

GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

About GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade